Roche acquires InterMune for $8.3 Billion

Roche acquires InterMune for $8.3 Billion

Roche acquires InterMune for $8.3 Billion

Roche, the Swiss drug maker, agreed to acquire specialists in treatment for breathing diseases InterMune for $8.3 Billion. Under the terms of the deal, Roche will pay $74 a share in cash, its 38 percent premium toInterMune’s closing price. Closing of the transaction is expected to end of 2014.

“We are very pleased that we reached this agreement with InterMune. Our offer provides significant value to InterMune’s shareholders and this acquisition will complement Roche’s strengths in pulmonary therapy. We look forward to welcoming InterMune employees into the Roche Group and to making a difference for patients with idiopathic pulmonary fibrosis, a devastating disease.” said Severin Schwan, CEO of Roche

“This merger recognizes the significant value created by our team’s commitment, hard work and execution for more than a decade to develop and commercialize treatment options for IPF patients and their families. Roche shares our passion and commitment to the IPF community and to ensuring that pirfenidone is available as quickly as possible to patients in the United States, pending FDA approval. Roche’s global resources and scale will not only facilitate and accelerate our ability to deliver pirfenidone to more patients around the world, but also to realize our joint vision to bring additional innovative therapies to patients with respiratory diseases.” said Dan Welch, InterMune’s Chairman, CEO and President.

Roche advisors are Citigroup and the law firm Davis Polk & Wardwell. Goldman Sachs, Centerview Partners and the law firm Cravath, Swaine & Moore advised InterMune.

The deal is expected to close by end of year and will be approved in European Union, Canada and United States.

Mr. Stakebay says:

Pharmaceutical Giant Roche will gain a biotechnology drug maker with focus lung diseases with primary drug is pifendone, which help to treat idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis is irreversible, progressive and ultimately fatal disease characterized by progressive loss of lung function.

 

CEO of Roche Holding …………………………………….Severin Schwan PhD. ……………..(2008-present)…………CHF 13 201 000(2013)

Chairman, CEO and President of InterMune…………….Daniel G. Welch………………,…….(2008-present)……………..$ 2 922 000 (2013)

 

ROCHE HOLDING

INTERMUNE

Revenue

CHF  46.780 billion (2013)

 $ 70.34 million (2013)

Operating income

CHF  16.376 billion (2013)

 $ -198.62 million (2013)

Profit

CHF  11.373 billion (2013)

 $ – 219.57 million (2013)

Total assets

CHF 39.884 billion (2013)

 $ 462.63 million (2013)

Total Equity

CHF 21.241 billion (2013)

 $ 134.28 million (2013)

Employees

85 080 (2013)

353 (2013)

You Might Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>